.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

All News

Post-Marketing Surveillance Data Reinforce Trastuzumab Biosimilar Safety in HER2+ Gastric Cancer

August 5th 2025

By Deana Ferreri, PhD

Article

CT-P6 demonstrates strong efficacy and safety in HER2-positive advanced gastric cancer, achieving an 82% disease control rate in real-world settings.

The Top 5 Biosimilar Articles for the Week of July 28

August 1st 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of July 28, 2025.

Biosimilars News Roundup: July 2025

July 31st 2025

By Skylar Jeremias

Article

Explore the latest biosimilar developments, including legislative changes, new approvals, and challenges in understanding, shaping the future of affordable health care.

Adalimumab Biosimilar Maintains Effectiveness for Patients With Arthritis and Health Care Costs

July 30th 2025

By Cameron Santoro

Article

Patients with rheumatoid and psoriatic arthritis maintained stable disease activity and functional capacity, with even some improvement in ultrasound findings, after switching from original adalimumab to its biosimilar, GP2017.

Clearing the Thicket: New Report Outlines Legislative Fixes to Boost Biosimilar Access

July 29th 2025

By Skylar Jeremias

Article

Patent thickets hinder biosimilar access, driving up costs and delaying affordable treatments. Discover legislative solutions to enhance competition and patient care.

New Approvals Expand Access to Biosimilars for Ophthalmology, Bone, and Joint Conditions

July 28th 2025

By Skylar Jeremias

Article

Global regulatory advancements in biosimilars enhance access to affordable treatments for autoimmune disorders, bone diseases, and ophthalmic conditions.

Follow the Science: Bridging the Biosimilar Gap With Dr Hillel Cohen

July 27th 2025

By Skylar Jeremias

Podcast

Explore the evolving biosimilars landscape with expert insights on development, regulation, and global health harmonization in this engaging podcast episode.

The Top 5 Biosimilar Articles for the Week of July 21

July 25th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of July 21, 2025.

Bevacizumab Biosimilar Fills Gap for Retinal Disease With Encouraging Safety Data

July 23rd 2025

By Skylar Jeremias

Article

Real-world data confirm Mvasi's safety as a cost-effective alternative to reference bevacizumab (Avastin) for treating retinal conditions.

Data Show Comparable Efficacy, Added Cost Benefit With Adalimumab Biosimilar vs Humira

July 22nd 2025

By Skylar Jeremias

Article

Biosimilar IBI303 offers comparable effectiveness to Humira for ankylosing spondylitis, providing significant cost savings and improved patient retention rates.